DelveInsight’s ‘Castrate-Sensitive Prostate Cancer Market Insights, Epidemiology and Market Forecast – 2034’ report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Discover Key Insights into the Castrate-Sensitive Prostate Cancer Market with DelveInsight’s In-Depth Report @ Castrate-Sensitive Prostate Cancer Market Size
Key Takeaways from the Castrate-Sensitive Prostate Cancer Market
Stay ahead in the Castrate-Sensitive Prostate Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Castrate-Sensitive Prostate Cancer Market Outlook
Castrate-Sensitive Prostate Cancer Epidemiology Segmentation in the 7MM
Download the report to understand which factors are driving Castrate-Sensitive Prostate Cancer Epidemiology trends @ Castrate-Sensitive Prostate Cancer Prevalence
Castrate-Sensitive Prostate Cancer Marketed Drugs
Erleada (apalutamide; Janssen Pharmaceutical) is a next-generation oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC/HSPC).
It is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. In December 2019, the US FDA granted approval to Xtandi (enzalutamide; Astellas Pharma) for use in the treatment of patients with metastatic CSPC. Prior to this, Xtandi was approved for castration-resistant prostate cancer. This approval was based on findings from the ARCHES clinical trial. The median rPFS rates in the Xtandi were not reached and for placebo arms was 19.4 months, respectively. In addition to this, in ARCHES trial statistically significant improvement in time to initiation of a new antineoplastic therapy with enzalutamide vs. placebo. The most common adverse reactions that occurred more frequently in enzalutamide-treated patients in ARCHES were hot flush, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain.
Castrate-Sensitive Prostate Cancer Emerging Drugs
Keytruda, also known as pembrolizumab, is a PD-1 blocking antibody. It is product of Merck Sharp & Dohme. It is mainly used for cancers that are advanced, have spread to other parts of the body or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. It is approved for multiple types of cancer. This is currently being investigated in Phase III clinical trials in combination with Enzalutamide for the treatment of patients affected by mHSPC.
Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. This drug is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.
Myovant Sciences also investigating their candidate Relugolix for Androgen-sensitive advanced prostate cancer. A phase III HERO study (NCT03085095; Recruiting) currently ongoing to determine the benefit and safety of Relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (≤ 50 ng/dL [1.7 nmol/L] in participants with androgen-sensitive advanced prostate cancer. This is an international, randomized, open-label, parallel group efficacy and safety study.
Topsalysin (PRX302), an investigative agent of Sophiris Bio for localized prostate cancer. It is first-in-class transmembrane pore-forming protein, was genetically modified to be activated only by enzymatically-active PSA, which is produced in large quantities within the prostate of men with prostate cancer.
Advantagene is developing ProstAtak for the treatment of patients suffering from prostate cancer. ProstAtak jump-starts the body’s own immune system to detect and destroy recurring cancer cells. The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the “ULYSSES” trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). However, enrollment is still open for prostate cancer patients choosing radiation therapy as their primary treatment (PrTK03- NCT01436968).
To learn more about Castrate-Sensitive Prostate Cancer treatment guidelines, visit @ Castrate-Sensitive Prostate Cancer Treatment Market Landscape
Castrate-Sensitive Prostate Cancer Companies
Bristol-Myers Squibb, Myovant Sciences/Takeda, Merck Sharp & Dohme, Sophiris Bio, RhoVac, Advantagene and others.
Castrate-Sensitive Prostate Cancer Treatment Market
Prostate cancer is the second most common cancer in men can be categorized into castrate-sensitive (castration-sensitive prostate cancer [CSPC], and castration-resistant prostate cancer (mCRPC). This type of cancer only considered to be CSPC if it responds to medical or surgical treatment to lower a patient’s testosterone levels. For the treatment of CSPC, Androgen-deprivation therapy (ADT) has been the cornerstone of therapy. However, most metastatic CSPC ( mCSPC/HSPC ) cannot be cured by ADT, and re‐emerges as metastatic castration-resistant prostate cancer (mCRPC). The treatment landscape of CSPC was not evolved until recent years.
Castrate-Sensitive Prostate Cancer Market Outlook
The report’s outlook on the Castrate-Sensitive Prostate Cancer market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Castrate-Sensitive Prostate Cancer therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Castrate-Sensitive Prostate Cancer drug and late-stage pipeline therapy.
Learn more about the FDA-approved drugs for Castrate-Sensitive Prostate Cancer @ Drugs for Castrate-Sensitive Prostate Cancer Treatment
Scope of the Castrate-Sensitive Prostate Cancer Market Report
Table of Content
1. Key Insights
2. Executive Summary of CSPC/HSPC
3. SWOT Analysis of CSPC/HSPC
4. CSPC/HSPC: Market Overview at a Glance
5. CSPC/HSPC: Disease Background and Overview
6. Diagnosis
7. Epidemiology and Patient Population
8. EU-5 Country-wise Epidemiology
9. Japan
10. Current Treatment Practices: Prostate Cancer
11. Guideline of Prostate Cancer
12. Unmet Needs of Prostate Cancer
13. Marketed Therapies
14. Emerging Therapies
15. CSPC/HSPC: Seven Major Market Analysis
16. 7MM Market Size
17. Market Access and Reimbursement of CSPC
18. Market Drivers of CSPC
19. Market Barriers of CSPC
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
